Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin), Oral (for Prednisone)
01
Overview
Brentuximab vedotin + cyclophosphamide + doxorubicin + prednisone (abbreviated as BV-CHP) is a multi-agent chemotherapy regimen used for the treatment of CD30-positive lymphomas, notably previously untreated systemic anaplastic large cell lymphoma (sALCL) in adults and is being evaluated in high-risk classical Hodgkin lymphoma in pediatric and adolescent populations. Brentuximab vedotin is an antibody-drug conjugate that targets CD30, delivering a cytotoxic payload (monomethyl auristatin E) to CD30-expressing cells. Cyclophosphamide is an alkylating agent that crosslinks DNA. Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Together, this combination is intended to leverage targeted cytotoxicity, broad cytostatic and immunomodulatory action to treat aggressive CD30-positive lymphomas, particularly when standard regimens including vincristine or bleomycin are not used or are substituted[1][2][3].
- Brand names
- B-CAP
- Other names
- BV-CHPbrentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone
02
Targets
CD30 (CD30 antigen)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on brentuximab vedotin + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + cyclophosphamide + doxorubicin + prednisone.